| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 11/21/2013 | WO2013129935A4 Use of a particulate immunomodulator in cancer therapy |
| 11/21/2013 | WO2013128419A3 Pharmaceutical compositions comprising boronic acid compounds |
| 11/21/2013 | WO2013084147A3 Antibodies for epidermal growth factor receptor 3 (her3) |
| 11/21/2013 | WO2012142245A8 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use |
| 11/21/2013 | WO2012125438A8 Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| 11/21/2013 | WO2005042743A8 Humanization of antibodies |
| 11/21/2013 | US20130310562 Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors |
| 11/21/2013 | US20130310388 Modulators of TNF-Alpha Signaling |
| 11/21/2013 | US20130310335 Prolonged release bioadhesive therapeutic systems |
| 11/21/2013 | US20130310320 Boronic ester and acid compounds, synthesis and uses |
| 11/21/2013 | US20130309317 Food supplement increase cd34 stem cells and telomerase activity |
| 11/21/2013 | US20130309311 Pellet formulation for the treatment of the intestinal tract |
| 11/21/2013 | US20130309232 Vascular endothelial growth factor 2 |
| 11/21/2013 | US20130309231 Methods for using taci-immunoglobulin fusion proteins |
| 11/21/2013 | DE102004043153B4 Erfindung betreffend GLP-1 und Exendin Invention concerning GLP-1 and exendin |
| 11/20/2013 | EP2664618A2 Chemokine receptor modulators |
| 11/20/2013 | EP2664343A2 Suppression of cancer |
| 11/20/2013 | EP2664325A1 Methods for preventing or treating androgen mediated diseases |
| 11/20/2013 | EP2663641A1 Mirna for treating diseases and conditions associated with neo-angiogenesis |
| 11/20/2013 | EP2663579A2 Therapeutic antibodies against ror-1 protein and methods for use of same |
| 11/20/2013 | EP2663566A1 5-([1,2,3]triazole-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives |
| 11/20/2013 | EP2663564A1 Imidazo [4, 5 -c]quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor |
| 11/20/2013 | EP2663553A2 Quinoline and isoquinoline compounds and methods of use thereof |
| 11/20/2013 | EP2663550A2 Substituted benzoazepines as toll-like receptor modulators |
| 11/20/2013 | EP2663332A1 Enhancement of allogeneic hematopoietic stem cell transplantation |
| 11/20/2013 | EP2663320A1 Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma |
| 11/20/2013 | EP2663318A1 Pharmaceutical composition for treating cancer |
| 11/20/2013 | EP2663307A1 Anti-angiogenic compound |
| 11/20/2013 | EP2663305A1 Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| 11/20/2013 | EP2663303A1 Anticancer therapy with dual aurora kinase / mek inhibitors |
| 11/20/2013 | EP2663302A1 Use of simalikalactone e as an anticancer agent |
| 11/20/2013 | EP2663301A1 Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof |
| 11/20/2013 | EP2663286A1 Preventive effect of citrulline on the spontaneous development of tumors |
| 11/20/2013 | EP2663283A1 High drug load tablet formulation of brivanib alaninate |
| 11/20/2013 | EP2663189A1 Combination |
| 11/20/2013 | EP2419432B1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 11/20/2013 | EP2403832B1 N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| 11/20/2013 | EP2300437B1 Benzpyrazol derivatives as inhibitors of pi3 kinases |
| 11/20/2013 | EP2272869B1 Angiopoietin-2 specific binding agents |
| 11/20/2013 | EP2265616B1 Furo-and thieno[3,2-c]pyridines |
| 11/20/2013 | EP2265599B1 Crystal form of phenylaminopyrimidine derivative |
| 11/20/2013 | EP2251014B1 Combinations of an anti-cancer agent and a cholestanol derivative |
| 11/20/2013 | EP2205640B1 Antibodies that bind il-4 and/or il-13 and their uses |
| 11/20/2013 | EP2205610B1 Thienopyrimidiene derivatives as pi3k inhibitors |
| 11/20/2013 | EP2190849B1 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases |
| 11/20/2013 | EP2134374B1 Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours |
| 11/20/2013 | EP2108655B1 Immune-modulating peptide |
| 11/20/2013 | EP2075334B1 EG-VEGF nucleic acids and polypeptides and methods of use |
| 11/20/2013 | EP1802579B1 Derivatives of 3-arylaminopyridine |
| 11/20/2013 | EP1683520B1 Water-soluble prodrugs |
| 11/20/2013 | EP1662004B1 Method of preparing a proliferation-regulated recombinant adenoviral vector, kit and vector |
| 11/20/2013 | EP1651762B1 Small interfering rna specific to sub-units alpha, alpha' and beta of the kinase protein ck2, and the applications of the same |
| 11/20/2013 | EP1613628B1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 11/20/2013 | CN1832956B Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same |
| 11/20/2013 | CN103403014A O-(replaced benzyl)phosphoramidate and use thereof |
| 11/20/2013 | CN103403013A Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
| 11/20/2013 | CN103403010A Inhibitors of polo-like kinase |
| 11/20/2013 | CN103403006A 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| 11/20/2013 | CN103403005A 5-([1,2,3]triazole-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives |
| 11/20/2013 | CN103403002A Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| 11/20/2013 | CN103402995A Novel indole or indazole derivative or salt thereof |
| 11/20/2013 | CN103402993A Novel esters of 4,9-dihydroxy-naphtho[2,3-b]furans for disease therapies |
| 11/20/2013 | CN103402984A Novel kinase inhibitors |
| 11/20/2013 | CN103402977A Ingenol-3-acylates III and ingenol-3-carbamates |
| 11/20/2013 | CN103402969A 3-acyl-ingenols II |
| 11/20/2013 | CN103402542A Medicinal agent for inhibiting metastasis of malignant tumor |
| 11/20/2013 | CN103402537A Use of pegylated recombinant human arginase for treatment of leukemia |
| 11/20/2013 | CN103402519A Therapeutic agent for tumor |
| 11/20/2013 | CN103402518A Compositions comprising a PI3K inhibitor and a MEK inhibitor and their use for treating cancer |
| 11/20/2013 | CN103402505A Dual inhibitors of MET and VEGF for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
| 11/20/2013 | CN103397012A Novel asparaginase enzyme variants and uses thereof |
| 11/20/2013 | CN103396996A NK92 cell strain carrying TGF-betaRII and NKG2D genes, and preparation method and use thereof |
| 11/20/2013 | CN103396992A Culture and application of oligoclonal tumor-infiltrating lymphocytes for liver cancer |
| 11/20/2013 | CN103396890A Method for preparing stable bighead atractylodes rhizome volatile oil |
| 11/20/2013 | CN103396557A Multifunctional cationic polymer gene vector, and preparation method and application thereof |
| 11/20/2013 | CN103396491A Monoclonal antibodies against human anti-mullerian hormone type II receptor (AMHR-II), and manufacturing method thereof and application |
| 11/20/2013 | CN103396489A Engineered anti-IL-23p19 antibodies |
| 11/20/2013 | CN103396487A Anti-IGF antibodies |
| 11/20/2013 | CN103396485A Method and composition for targeting polyubiquitin |
| 11/20/2013 | CN103396474A APJ receptor compound |
| 11/20/2013 | CN103396473A Cxcr4 receptor compound |
| 11/20/2013 | CN103396470A Withanolides type compounds and antitumor use thereof |
| 11/20/2013 | CN103396456A Divalent double-core platinum complex and preparation method thereof |
| 11/20/2013 | CN103396437A Bi(tricyclohexyl tin) dicarboxylic ester and preparation method and application thereof |
| 11/20/2013 | CN103396436A Monobutyltin trichloride substituted salicylidenedimine Schiff base complex as well as preparation method and applications thereof |
| 11/20/2013 | CN103396435A Dibutyl tin aromatic aldehyde condensed arylamine Schiff base complex as well as preparation method and application thereof |
| 11/20/2013 | CN103396426A Chiral boric acid derivative as well as preparation method and application thereof |
| 11/20/2013 | CN103396419A Tumour photodynamic therapy medicine dihydroporphin e6-15-ethyl ester and preparation method thereof |
| 11/20/2013 | CN103396417A Novel hydroxamic acid derivative and medical application thereof |
| 11/20/2013 | CN103396415A Novel substituted imidazoquinolines |
| 11/20/2013 | CN103396414A Imidazolyl-substituted thiazocyclohexane compounds and antitumor application thereof |
| 11/20/2013 | CN103396409A Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| 11/20/2013 | CN103396405A Benzimidazole-4-formamide derivate with PARP (poly-ADP-ribose polymerase) inhibiting effect |
| 11/20/2013 | CN103396400A Pyrazole amide compounds, and preparation method and application thereof |
| 11/20/2013 | CN103396397A Lenalidomide derivative and use thereof as medicine |
| 11/20/2013 | CN103396389A Naphthoquinone sesquiterpenes compound and application thereof in preparation of anti-tumour or antibacterial medicine |
| 11/20/2013 | CN103396386A Di-substituted dinaphtho-[2,1-b:1',2'-d] furan derivative as well as preparation method and application thereof |
| 11/20/2013 | CN103396376A Anti-bacterial and anti-cancer active compound |
| 11/20/2013 | CN103396361A 3, 4-dihydroisoquinoline antitumor compounds as well as preparation method and application thereof |
| 11/20/2013 | CN103396351A Pyrrolidone Bc1-2 protein small-molecule inhibitor compound, and preparation, pharmaceutical composition and pharmaceutical use thereof |